Eslicarbazepine acetate: A double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures

Epilepsia

Volumn 48, Issue 3, 2007, Pages 497-504

  Elger, Christian ^a   Bialer, Meir ^b   Cramer, Joyce A ^c   Maia, Joana ^d   Almeida, Luis ^d   Soares Da Silva, Patrício ^d  

^a UNIVERSITY OF BONN   (Germany)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

Add on therapy; Antiepileptic drugs; BIA 2 093; Epilepsy; Eslicarbazepine acetate; Partial seizures

Indexed keywords

ANTICONVULSIVE AGENT; BIA 2093; CLONAZEPAM; ESLICARBAZEPINE ACETATE; LAMOTRIGINE; PHENYTOIN; PLACEBO; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADD ON THERAPY; ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; ELECTROLYTE DISTURBANCE; FEMALE; FOCAL EPILEPSY; HAIR LOSS; HEADACHE; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SODIUM BLOOD LEVEL; SOMNOLENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; ANTICONVULSANTS; DIBENZAZEPINES; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME;

EID: 33847611166     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.00984.x     Document Type: Article

References (18)

1. Almeida L, Soares-da-Silva P. (2003) Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs in R&D 4:269-284.
2. Almeida L, Soares-da-Silva P. (2004) Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. Journal of Clinical Pharmacology 44: 906-918.
3. Almeida L, Falcão A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. (2005a) Single dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. Journal of Clinical Pharmacology 45:1062-1066.
4. Almeida L, Maia J, Soares-da-Silva P. (2005b) A double-blind, add-on, placebo controlled exploratory trail of eslicarbazepine acetate in patients with partial-onset seizures. Epilepsia 46(suppl 8):167-168.
5. Ambrosio AF, Silva AP, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM. (2001) Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochemical Pharmacology 61:1271-1275.
6. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. (2002) Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochemical Research 27:121-130.
7. Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, Cunha RA, Garrett J, Soares-da-Silva P. (1999) Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5- carboxamide derivatives. Journal of Medicinal Chemistry 42:2582-2587.
8. Bialer M, Johannessen S, Kupferberg Levy R, Loiseau P, Perucca E. (2004) Progress report on new antiepileptic drugs: a summary of the Seventh EILAT Conference (EILAT VII). Epilepsy Research 61:1-48.
9. Bonifacio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-da-Silva P. (2001) Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 4:600-608.
10. Burneo GB, Montori VM, Faught E. (2002) Magnitude of placebo effect in randomized trials of antiepileptic agents. Epilepsy Behavior 3:532-534.
11. Fontes-Ribeiro C, Nunes T, Falcão A, Neta C, Lima R, Tavares S, Almeida L, Macedo T, Soares-da-Silva P. (2005) Eslicarbazepine acetate (BIA 2-093): relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200 mg and 800 mg tablet formulations. Drugs in R&D 6:253-260.
12. Hainzl D, Parada A, Soares-da-Silva P. (2001) Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Research 44:197-206.
13. Kuz GM, Manssourian A. (2005) Carbamazepine-induced hyponatremia: assessment of risk factors. Annals of Pharmacotherapy 39:1943-1946.
14. Maia J, Vaz-da-Silva M, Almeida L, Falcão A, Silveira P, Guimarães S, Graziela P, Soares-da-Silva P. (2005) Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs in R&D 6:201-206.
15. Niklson I, Edrich P, Verdru P. (2006) Identifying baseline characteristics of placebo responders versus nonresponders in randomized doubleblind trials of refractory partial-onset seizures. Epilepsy Research 8:37-44.
16. Schmidt D, Sachdeo R. (2000) Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behavior 1:396-405.
17. Silveira P, Falcão A, Almeida L, Maia J, Soares-da-Silva P. (2004) BIA 2-093 pharmacokinetics in healthy elderly subjects (abstract). Epilepsia 45(suppl 3):157.
18. Vaz-da-Silva M, Nunes T, Soares E, Rocha JF, Tavares S, Falcão A, Almeida L, Soares-da-Silva P. (2005) Eslicarbazepine acetate pharmacokinetics after single and repeated doses in healthy subjects (abstract). Epilepsia 46(suppl 8):191.